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The concept of the Heart Team – consisting of at least a
cardiac surgeon and an interventional cardiologist – in guiding
decision making on the optimal revascularization modality in
patients with complex coronary artery disease (CAD) has had a
relatively short history.1,2 Prior to the publication of the
landmark randomized SYNTAX Trial in 2009,1–4 decision-
making between coronary artery bypass graft (CABG) surgery
and percutaneous coronary intervention (PCI) in patients with
complex CAD was very much at the discretion of the
interventional cardiologist, who acted as the ‘‘gate-keeper’’.
Such an approach appropriately drew heavy criticism from
cardiac surgeons and the cardiology community alike, since
patients with complex CAD were being denied evidence-based
surgical revascularization, and undergoing the then non-
evidenced-based practice of multivessel PCI.5,6 SYNTAX
represented the largest assessment of revascularization with
CABG or PCI in subjects with complex CAD, and aimed to
supply a body of evidence to support the rapidly expanding
practice of multivessel PCI. In addition, through an all-comers,
randomized trial design, SYNTAX aimed to eliminate the
profound selection bias that had plagued earlier trials
comparing CABG and PCI. Namely, that these trials enrolled
highly selected, ‘‘cherry-picked,’’ patients, with less complex
coronary anatomy (predominantly single or double vessel
disease) and lower co-morbidity (such as impaired leftventricular function), and thus being largely unrepresentative
of conventional clinical practice.5,7,8
One of the unique aspects of the SYNTAX Trial was that a
Heart Team – consisting of at least a cardiac surgeon and an
interventional cardiologist – was required to use the SYNTAX
score (www.syntaxscore.com) as an objective anatomical
scoring tool that forced the Heart Team to systematically
analyze the coronary angiogram, and agree that equivalent
anatomic revascularization between CABG and PCI could be
achieved, based on a vessel size of 1.5 mm. Subjects were
randomized if the Heart Team agreed that equivalent
anatomic revascularization could be achieved; subjects not
suitable for randomization were nested in CABG (PCI-ineligible
patients for predominantly too complex CAD that could not
be revascularized to the same extent as CABG) and PCI (CABG-
ineligible patients for predominantly too high operative risk)
registries and followed up.1
Since publication of the SYNTAX Trial, it is noteworthy that
both the Heart Team approach and the anatomical SYNTAX
score are advocated in both European and US revasculariza-
tion guidelines,9–15 with the Heart Team given a class 1
recommendation.
1. Does the Heart Team have the appropriate
clinical tools to aid decision making?
One may argue that the Heart Team, in open dialog with the
patient, allows for a consensus to be reached that would only
Fig. 1 – Complex coronary artery disease – the Heart Team in action. Key factors in guiding decision-making on the optimal
revascularization strategy in patients with complex coronary artery disease. The Heart Team must balance patient wishes,
clinical evidence and approved international revascularization guidelines, ability to achieve equivalent anatomical
revascularization, and clinical symptoms, when determining the most appropriate revascularization strategy. Various
clinical tools are available to aid the Heart Team approach, and allow for more objective decision-making. These include
assessment of anatomical complexity (SYNTAX score), anatomical complexity augmented with clinical variables (SYNTAX
score II), surgical operative risk tools (e.g. EuroSCORE, STS score), and tools to aid in the assessment of completeness of
revascularization (e.g. residual SYNTAX score35). In addition, the involvement of necessary multidisciplinary specialties and
the patient are required to facilitate shared decision-making. Abbreviations: CABG – coronary artery bypass graft surgery,
LVEF – left ventricular ejection fraction, FEV1 – forced expiratory volume in 1 s, PCI – percutaneous coronary intervention.
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modality based on the best available clinical evidence. Such
a practice has been shown to reduce physician bias and allows
for guideline directed decision-making.16–18 One may however
ask in retort, can the Heart Team really assimilate all the
clinical evidence to help direct appropriate decision-making?
Fig. 1 illustrates this complex relationship, which may be
regarded as a set of scales, with factors pushing toward either
surgical or percutaneous-based revascularization. Clinical
tools such as the anatomical SYNTAX score and SYNTAX
score II are detailed below to aid the Heart Team in simplifying
this process. The development of non-invasive anatomical
assessments (with for example a multislice computed tomog-
raphy [MSCT] derived SYNTAX score) is ongoing, and will
ultimately serve to streamline the Heart Team process by
allowing for non-invasive decision-making.19,20
1.1. Anatomical SYNTAX score
Based primarily on the results of SYNTAX, current European
revascularization guidelines10 gives subjects with three vessel
diseases and low SYNTAX scores (0–22), a level of evidence of
IA for CABG and IIa B for PCI. In subjects with unprotected left
main coronary artery (ULMCA) disease and low to intermedi-
ate SYNTAX scores (<33), a level of evidence of IA is given for
CABG and IIb B for PCI. Furthermore, US guidelines now givesurgical revascularization for ULMCA disease a Class 1B
recommendation,11,12 compared to a Class 1A recommenda-
tion in previous guidelines.21
The randomized EXCEL (Evaluation of XIENCE PRIMETM or
XIENCE V® Everolimus Eluting Stent System Versus Coronary
Artery Bypass Surgery for Effectiveness of Left Main Revascu-
larization; ClinicalTrials.gov identiﬁer: NCT01205776) and
NOBLE (Nordic-Baltic-British Left Main Revascularization
Study, ClinicalTrials.gov Identiﬁer: NCT01496651) trials will
ultimately provide a much stronger evidence base for the
practice of left main intervention. EXCEL recently completed
recruitment of 1905 patients with ULMCA disease and
investigator reported SYNTAX scores <33, randomized to
CABG (n = 957) or PCI with contemporary stents (n = 948). The
Primary Endpoint is a composite measure of all-cause death,
MI, or stroke at 3 years post revascularization.22
1.2. SYNTAX score II
The SYNTAX score II23–25 augments the purely anatomical
SYNTAX score with anatomical and clinical factors that were
shown to alter the threshold value of the anatomical SYNTAX
score that would lead to similar long-term mortality between
CABG and PCI. Based on this principle, younger age, female
gender and reduced LVEF favored CABG compared to PCI
on long-term prognostic grounds. Thus, in such patients, a
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to achieve a similar long-term mortality between CABG and
PCI. By contrast, older age, chronic obstructive pulmonary
disease or ULMCA disease favored PCI compared to CABG and
thus, in this type of patient, a HIGHER anatomical SYNTAX
score would be needed for the long-term mortality between
CABG and PCI to be similar.
The above ﬁndings are supported from a recent sub
analysis of the Surgical Treatment of IsChemic Heart failure
(STICH) Trial26 demonstrating that in subjects with more
advanced ischemic cardiomyopathy, more extensive CAD and
worse myocardial dysfunction and remodeling, that a net
longer-term prognostic beneﬁt was seen for CABG compared
to optimal medical therapy, despite the short term (30-day)
mortality risk being higher with CABG. In addition, a
population-based study of patients with chronic kidney
disease and multivessel coronary disease from the Ontario
provincial registry, demonstrated that CABG was associated
with improved early and late mortality beneﬁt compared to
PCI.27 Findings that raise the possibility that excess plaque
burden and vulnerability may play a role in decision-making
between CABG and PCI.28 Namely, that patients with these
characteristics are more likely to derive a longer-term
prognostic beneﬁt from surgical revascularization, despite
the potentially higher operative risks associated with reduced
left ventricular ejection fraction or impaired kidney function.
Findings which may in part be due to the potential protective
effects of a bypass graft in passivating the entire vessel from
future cardiac events for the lifespan of the graft – unlike PCI
which would treat the obstructive lesion alone.5,23,27,29
External validation of the SYNTAX score II has retrospec-
tively been performed in the multinational Drug Eluting stent
for Left main coronary Artery disease (DELTA) Registry
(n = 2891; 14 centers in Europe, US and South Korea),30 and
the Japanese Coronary REvascularization Demonstrating
Outcome Study in Kyoto (CREDO-Kyoto) PCI/CABG multicenter
registry (n = 1796).31 Prospective validation of the SYNTAX
score II is currently ongoing in EXCEL and the SYNTAX II
(ClinicalTrials.gov Identiﬁer: NCT02015832) trials. As part
of the prospective validation of the SYNTAX score II in EXCEL,
the SYNTAX score II has predicted at least an equipoise for
long-term mortality between CABG and PCI in subjects with
ULMCA disease up to an intermediate anatomical complexity
(anatomical SYNTAX score <33).25
2. Indian subcontinent
Against this backdrop, in this issue of The Indian Heart Journal,
are two important, real world, single center registries from
India (Ray et al., Goel et al.)32,33 describing outcomes relating to
unprotected left main PCI. It is noteworthy that both registries,
despite their limited size, support the EXCEL hypothesis as
described earlier. Namely, that there was a clear difference in
outcomes between low to intermediate SYNTAX scores (<33)
and high SYNTAX scores (>32), the latter of which was shown
to be an independent predictor of adverse clinical outcomes in
both registries. In addition, these ﬁndings support the concept
that it is not the presence of left main disease per se that drives
adverse clinical outcomes and decision making between CABGand PCI, but the complexity of the CAD downstream from the
left main.23 The more complex the downstream CAD, the
greater plaque burden/vulnerability necessitating the poten-
tial protective effects of a bypass graft.5,23,27,29 It has previously
been hypothesized that the presence of left main disease is
akin to single vessel,20,23 and provided that the interventional
center has the technical ability to perform the procedure safely
and efﬁcaciously; outcomes are excellent.
Another notable observation is that Ray et al.32 demonstrat-
ed that impaired left ventricular function to be an independent
predictor of adverse outcomes in patients undergoing left main
PCI. Such ﬁndings were also seen in the SYNTAX Trial during
development of the SYNTAX score II, where it was shown that
much lower anatomical SYNTAX scores were required for
equipoise for long-term mortality between CABG and PCI.23 In
addition, Ray et al. elegantly demonstrated that distal left main
disease was only associated with an excess hazard of adverse
outcomes in the presence of high SYNTAX scores (>32).
Findings that again support the EXCEL hypothesis, and the fact
that outcomes related to distal (bifurcation) left main disease
are confounded by the complexity of the downstream CAD,
and it is the latter that drives adverse outcomes, not the
presence of distal left main disease per se.
It is however important to emphasize that the concept of the
Heart Team is not yet an accepted part of mainstream practice
in India, and as a consequence, left main PCI may be being over
utilized (Personal Communication: Professor Sundeep Mishra,
Editor-in-Chief, Indian Heart Journal, 5th July 2015). In the two
registries described in this issue of the Indian Heart Journal,32,33
one describes the use of a multidisciplinary Heart Team
approach and the other does not. Given the complexity of
decision making (Fig. 1), danger of physician bias as previously
described,5,16–18 the awaited outcomes from EXCEL/NOBLE, and
prospective validation studies of the SYNTAX score II, the logic
of not adopting a Heart Team approach to ensure decision
making is made on the best available clinical evidence and
guidelines, is difﬁcult to comprehend. Whether one wishes to
use Western guidelines or develop local guidelines that may be
more relevant to Indian practice is of course welcomed.34
Decision-making based on the best available clinical evidence
and the consensus of the Heart Team should ultimately be the
idealism we should strive for. Ensuring the social and political
will is present will guarantee that the Heart Team concept is
built on a solid foundation that will ultimately serve to
safeguard the welfare of our patients we treat every day. . .
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